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Subcortical volumetric brain abnormalities have been observed in mood disorders. However, it is un-
known whether these reﬂect adverse effects predisposing to mood disorders or emerge at illness onset.
Magnetic resonance imaging was conducted at baseline and after two years in 111 initially unaffected
young adults at increased risk of mood disorders because of a close family history of bipolar disorder and
93 healthy controls (HC). During the follow-up, 20 high-risk subjects developed major depressive dis-
order (HR-MDD), with the others remaining well (HR-well). Volumes of the lateral ventricles, caudate,
putamen, pallidum, thalamus, hippocampus and amygdala were extracted for each hemisphere. Using
linear mixed-effects models, differences and longitudinal changes in subcortical volumes were in-
vestigated between groups (HC, HR-MDD, HR-well). There were no signiﬁcant differences for any sub-
cortical volume between groups controlling for multiple testing. Additionally, no signiﬁcant differences
emerged between groups over time. Our results indicate that volumetric subcortical brain abnormalities
of these regions using the current method appear not to form familial trait markers for vulnerability to
mood disorders in close relatives of bipolar disorder patients over the two-year time period studied.
Moreover, they do not appear to reduce in response to illness onset at least for the time period studied.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The common psychopathological symptom in mood disorders
such as bipolar disorder (BD) and major depressive disorder
(MDD) is a disturbance in the person's mood (World Health Or-
ganization, 2004). Several lines of evidence indicate that there is
an overlap in the pathophysiological mechanisms underlying the
pathogenesis of BD and MDD. First of all, mood disorders com-
monly aggregate within families, with ﬁrst-degree relatives of BD
patients having a 10-fold increased risk of BD and a 3-fold excess
risk of MDD as compared to the general population (Smoller and
Finn, 2003). Moreover, moderate to high heritability estimates
have been found and recent ﬁndings indicate that both conditions
share underlying genetic risk factors (Craddock, 2006; Cross-r Ireland Ltd. This is an open acces
niversity of Edinburgh, Royal
10 5HF, United Kingdom.
(M. Papmeyer).Disorder Group of the Psychiatric Genomics Consortium, 2013;
McGufﬁn et al., 2003; Schulze et al., 2014).
Using region-of-interest (ROI) manual tracing, semi-automated
segmentation methods or voxel-based morphometry analyses,
structural magnetic resonance imaging (MRI) studies have re-
peatedly shown that gray matter abnormalities in subcortical brain
regions are associated with mood disorders (Beyer and Krishnan,
2002; Konarski et al., 2008; Savitz and Drevets, 2009). Most con-
sistently, meta- and mega-analyses have detected a signiﬁcant
enlargement of the lateral ventricles in both MDD and BD patients
(Arnone et al., 2009; Hallahan et al., 2011; Kempton et al., 2008,
2011; McDonald et al., 2004). It has been hypothesized that this
ventricular abnormality may reﬂect medial temporal lobe, lateral
prefrontal cortex or basal ganglia volume reductions (Savitz and
Drevets, 2009). Furthermore, reduced basal ganglia volumes of the
caudate, putamen and pallidum have been repeatedly found in
MDD (Arnone et al., 2012; Bora et al., 2012; Kempton et al., 2011;
Koolschijn et al., 2009), while ﬁndings in BD have been largely
inconsistent, with volumes being either increased (Arnone et al.,s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 2008; McDonald et al., 2004). In MDD (Arnone et al., 2012;
Kempton et al., 2011; Koolschijn et al., 2009) but not BD patients
(Arnone et al., 2009; Hallahan et al., 2011; Kempton et al., 2008),
the thalamus and hippocampus have been found to be reduced. Of
note, some recent individual voxel-based morphometry or seg-
mentation-based studies did also detect reduced hippocampal
gray matter volumes in BD patients (Quigley et al., 2015; Redlich
et al., 2014). Finally, there is some evidence for volume reductions
of the amygdala in both conditions (Bora et al., 2012; Hallahan
et al., 2011). However, the majority of meta-analyses have not
detected amygdala volume abnormalities in MDD or BD patients
(Arnone et al., 2009, 2012; Kempton et al., 2008; Koolschijn et al.,
2009; McDonald et al., 2004). Importantly, a large heterogeneity in
ﬁndings has been observed for the amygdala, with smaller
amygdala volumes being particularly observed in paediatric, ado-
lescent and young adult MDD or BD subjects and larger volumes
being most frequently found in older age for both conditions
(Konarski et al., 2008; Schmaal et al., 2015). Moreover, research
indicates that family history for depression and gender impact on
the volume of the amygdala, providing a further rationale for the
heterogeneous ﬁndings concerning amygdala volumes in MDD
(Saleh et al., 2012). In detail, a positive family history for depres-
sion in female but not male MDD patients has been associated
with smaller amygdala volumes, whereas depression without a
positive family history has been associated with increased amyg-
dala volumes (Saleh et al., 2012).
The subcortical brain regions outlined are of particular interest
for the pathogenesis of mood disorders as they are closely in-
volved in affect regulation and emotion processing – functions
clearly disturbed in mood disorders (Phillips et al., 2003a, 2003b).
The amygdala, ventral striatum, thalamus and hippocampus are
selectively interconnected with distinct prefrontal and anterior
cingulate brain regions in two relatively discrete neural systems.
Accordingly, it has been postulated that dysfunction in speciﬁc
components of these neural systems could be centrally involved in
the mood dysregulation observed in BD and MDD (Phillips et al.,
2003b).
The aetiology of the commonly observed subcortical brain ab-
normalities in mood disorders remains relatively unknown as
most brain imaging research has focussed on brain structure in
individuals already affected by the disease. Accordingly, they
cannot provide information whether volumetric brain abnormal-
ities represent early neurodevelopment disturbances that are
present prior to illness onset, emerge in response to pathological
processes occurring close to illness onset, or whether they re-
present the effects of chronic illness or medication. Neuroimaging
investigations of individuals at high familial risk of mood disorders
may help to detect structural brain abnormalities associated with
familial vulnerability, unconfounded by illness and medication
effects. However, only few studies have examined subcortical gray
matter volumes in unaffected close relatives of BD patients as yet.
These have yielded largely heterogeneous results (Nery et al.,
2013), with a recent meta-analysis indicating no evidence towards
subcortical gray matter abnormalities (Fusar-Poli et al., 2012). It
appears plausible that the inconsistency in ﬁndings, in particular
with regard to the amygdala, is partly related to factors that have
been found to inﬂuence subcortical brain volumes in affected pa-
tients such as age and gender as outlined earlier. To the best of our
knowledge, no study has yet examined prospectively and long-
itudinally the effects of the presence of familial risk on subcortical
gray matter volumes.
The Bipolar Family Study allows investigating the time course
of volumetric subcortical brain abnormalities in mood disorders
and their association with familial risk and illness onset. We have
previously shown that reduced right parahippocampal andfusiform gyrus thickness across time as well as progressive cortical
thinning in the left inferior frontal and precentral gyri over time
are familial vulnerability marker for mood disorders (Papmeyer
et al., 2015). Moreover, we found the onset of depression to be
associated with abnormal left inferior frontal and precentral
thickness development over time in this study cohort (Papmeyer
et al., 2015). However, subcortical brain volumes of our study co-
hort have not been studied as yet.
Based on the literature review presented above, we compared
the volumes of the lateral ventricles, caudate, putamen, pallidum,
thalamus, hippocampus and amygdala for each hemisphere over a
two-year time interval between three groups: individuals at high
risk of mood disorders who were not affected by mood disorders
at study entry but had an onset of MDD during the follow-up time
(HR-MDD), individuals at high risk who remained unaffected by
mood disorders during the identical time period (HR-well), and
healthy control individuals (HC). All study participants were re-
cruited during late adolescence or early adulthood. Given the re-
latively young age of our participants and the observed associa-
tions between small amygdala volumes and a positive family
history for depression and young age in mood disorders patients,
we hypothesised that reduced volume of the amygdala is asso-
ciated with familial risk for mood disorders and is thus present in
unaffected close BD relatives. Moreover, we hypothesised that
subcortical regions commonly reduced in mood disorders patients
reduce in volume progressively in the two-year follow-up period
prior to illness and that the onset of MDD results in more pro-
nounced volume reductions as compared to high-risk individuals
who remain unaffected by the disorder.2. Methods
2.1. Participants
All participants for this research project were recruited as part of the Bipolar
Family Study (Sprooten et al., 2011; Whalley et al., 2011). Individuals at high risk of
mood disorders because of a close family history of BD were identiﬁed via affected
relatives. They were considered at increased risk of mood disorders because of the
known cross-over of risk between BD and MDD. Across Scotland, psychiatrists re-
ferred patients to the study with a primary diagnosis of BD, type I. To conﬁrm a
diagnosis in affected subjects, the Operational Criteria Symptom Checklist
(McGufﬁn et al., 1991) using information from clinical case notes and the Structured
Clinical Interview for DSM-IV Axis-I Disorders (First et al., 1996) were employed.
The BD patients were asked to identify close family members between 16 and 25
years of age. Following informed consent, unaffected individuals with at least one
ﬁrst degree, or two second degree relatives with type I BD were invited to take part
in the study. All high risk of mood disorders participants were interviewed to
conﬁrm a lifetime absence of mood disorders or schizophrenia and to ensure that
they did not meet any exclusion criteria outlined below.
Healthy unrelated control subjects with no personal or family history of BD
were identiﬁed from the social contacts of the high-risk participants and group-
matched for age, sex and premorbid intelligence estimated with the National Adult
Reading Test (Nelson, 1982). To screen for Axis-I disorders, the Structured Clinical
Interview for DSM-IV Axis-I Disorders (First et al., 1996) was used.
The exclusion criteria for all study groups at baseline included a personal his-
tory of MDD, mania or hypomania, psychosis, or any major neurological or psy-
chiatric disorder, substance dependence, learning disability, head injury that in-
cluded loss of consciousness and any contraindications to MRI.
Approximately two years after study entry, all study participants were invited
for a follow-up appointment. All subjects provided written informed consent and
the study was approved by the Research Ethics Committee for Scotland.
2.2. Clinical assessment
Clinical assessments were carried out on the same day as the ﬁrst and second
MRI scan. The average time interval in years between the two visits was 2.13 (SD
0.22), 2.15 (SD 0.22), 2.10 (SD 0.13) for the HC, HR-well and HR-MDD group. To
determine the diagnostic status of consenting subjects who did not return for a
second visit, the National Health Service was contacted. Two experienced psy-
chiatrists conducted the clinical interviews (AMM, JES). On the basis of the follow-
up clinical assessment or information from case notes, individuals at high risk of
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who developed MDD after study entry (HR-MDD). Current manic and depressive
symptoms were determined at baseline and follow-up assessments with the Young
Mania Rating Scale (Young et al., 2000) and Hamilton Depression Rating Scale
(Hamilton, 1960).
2.3. Magnetic resonance imaging acquisition
Imaging at both time points was carried out at the Brain Imaging Research
Centre (BIRC) for Scotland on a GE 1.5 T Signa scanner (GE Medical, Milwaukee,
USA). The T1 sequence was a coronal gradient echo sequence with magnetisation
preparation (MPRAGE) and yielded 180 contiguous 1.2 mm coronal slices (TI¼500
ms; TE¼4 ms; matrix¼192192; ﬂip angle¼8°).
2.4. Subcortical volume segmentations
The T1 images were processed using the volume-based stream in FreeSurfer
version 5.1.0 (http://surfer.nmr.mgh.harvard.edu), described in detail by Fischl et al.
(2002). In short, intensity normalisation was conducted, followed by removal of
non-brain tissue using a hybrid watershed/surface deformation procedure. Next,
neuroanatomical labels were assigned to each voxel in an MRI volume based on
probabilistic information derived from a manually labelled training set. The accu-
racy of the ﬁnal subcortical brain segmentations was visually inspected and edited
where needed according to the standard FreeSurfer guidelines (http://surfer.nmr.
mgh.harvard.edu/fswiki/Edits) by a single rater, blind to diagnostic status (MP).
The following regions of interest (ROI) were extracted for each hemisphere
(Fig. 1): lateral ventricles, caudate, putamen, pallidum, hippocampus, thalamus,
amygdala. We decided to compare the volumes of these subcortical brain regions
separately for each hemisphere since some ﬁndings in unaffected relatives of BD
patients or ﬁrst-episode MDD patients point towards speciﬁc lateralisation effects
(Frodl et al., 2002; Nery et al., 2013). In addition, intra-cranial volume of the whole
brain was extracted to serve as a covariate.
2.5. Statistical analyses
The statistical analyses were conducted using SPSS version 19 (http://www.
spss.com), except for False Discovery Rate (FDR) corrections (Benjamini and
Hochberg, 1995) which were computed using the ‘p.adjust(BH)’ function of the
‘stats’ package in R version 2.13.0 (http://www.r-project.org). Demographic and
clinical data analyses were conducted using one-way analyses of variance (ANOVA),
chi-squares tests or Kruskal-Wallis tests where appropriate.
Linear mixed-effects models were applied to analyse structural brain differ-
ences between groups for each ROI over time. These models have several ad-
vantages over repeated measures ANOVAs as they take the correlation structures of
repeated measurements nested within participants into account and do not require
casewise deletion of missing data so that all available data can be analysed. In the
linear mixed-effects model used, the intercept term is entered as a random effect
that varies by individual so that intraindividual correlation among the volumetric
brain measures of a given subject is taken into account. The following independent
variables were used as predictors of subcortical brain volume for the different ROIs:
group, time (baseline versus follow-up assessment), group-by-time interaction.
Age, sex and intracranial volume served as covariates. Accordingly, differences inFig. 1. Subcortical regions of interest. Three-dimensional representation of the
subcortical regions of interest extracted with FreeSurfer. Not shown: amygdala.
Abbreviations: Ca, caudate; Hi, hippocampus; Lv, lateral ventricles; Pa, pallidum;
Pu, putamen; Th, thalamus.subcortical brain volume between the groups across both time points are re-
presented by signiﬁcant group effects. Differences in subcortical brain volume
between baseline and follow-up examination are represented as time effects. Dif-
ferences in subcortical brain volume development over time between groups are
represented as group-by-time interactions.
A statistical signiﬁcance level of pFDRr0.05 was selected, fully corrected for
multiple comparisons using the Benjamini & Hochberg FDR procedure (Benjamini
and Hochberg, 1995). For ease of comparison with future results, we report the
original uncorrected p-values (puncorrected) and whether they survived the FDR
threshold. Wherever signiﬁcant effects were found, pairwise comparisons were
conducted between the three groups, with p-values being corrected according to
Tukey's “Honest signiﬁcance difference” method (pHSDr0.05).
The putative relationship between depressive symptom severity and sub-
cortical brain volumes was examined by calculating the Spearman correlation
coefﬁcient between the Hamilton Depression Rating Scale total score and the ROIs
for each group. For all analyses, p-values were corrected using the FDR procedure
and considered signiﬁcant when pFDRr0.05.
To assess potentially confounding effects of medication and familial relatedness
of subjects on the volumes of the ROIs, we conducted the following supplemental
analyses for signiﬁcant results: First, we repeated our analyses excluding medicated
HR-MDD subjects (n¼4). Second, we randomly excluded related subjects from the
analyses (n¼2 HC; n¼17 HR-well; n¼2 HR-MDD).3. Results
3.1. Demographic and clinical characteristics
FreeSurfer processed MRI scans of good quality along with
clinical data were available for 114 high-risk individuals at base-
line. Two of these individuals had developed BD during the two-
year follow-up time and were excluded from all analyses because
of their small sample size. In total, 20 high-risk subjects had an
onset of MDD during the two-year follow-up period. However, one
of them was excluded from baseline analysis due to the un-
satisfactory subcortical segmentations of the MRI scan. Accord-
ingly, our analyses included 92 HR-well and 19 HR-MDD subjects
at baseline. There were 96 HC subjects that provided MRI data of
good quality along with clinical information at baseline. Three of
them had an onset of MDD during the follow-up time and were
thus excluded from all analyses, resulting in a sample size of 93 HC
participants. At follow-up examination, there were 63 HR-well, 20
HR-MDD, and 62 HC subjects with suitable processed MRI scans
together with clinical data. Among the HR-MDD participants, four
were receiving antidepressant medication at follow-up. Three in-
dividuals were taking selective serotonin reuptake inhibitors
(1citalopram, 1 ﬂuoxetine, 1 sertraline) and one participant was on
a tricyclic antidepressant (lofepramine). The remaining 16 HR-
MDD subjects were unmedicated.
No signiﬁcant differences between the groups emerged in
terms of age, gender, handedness, verbal intelligence and Young
Mania Rating Scale total score at any assessment point (Table 1).
However, there were signiﬁcant group differences at baseline
(pr0.007) and follow-up (pr0.023) for clinical measures of de-
pression using the Hamilton Depression Rating Scale. At baseline,
HR-well and HR-MDD participants had signiﬁcantly higher de-
pression sum scores (pr0.047 and pr0.003, respectively) than
HC subjects, with no signiﬁcant differences between the two high-
risk groups. At follow-up, HR-MDD subjects had higher depression
sum scores than HC and HR-well individuals (pr0.013 and
pr0.010, respectively) as expected, with no signiﬁcant differences
between HC and HR-well individuals.
3.2. Subcortical brain volumes
The linear mixed-effects model analyses revealed no signiﬁcant
effects of group after correction for multiple testing. Also, no sig-
niﬁcant effects of time or group-by-time interactions for any ROI
volume were observed after correction for multiple testing (Table 2).
Table 1
Demographic and clinical characteristics.
Baseline Follow-up
HC (n¼93) HR-well (n¼92) HR-MDD (n¼19) Statistics HC (n¼62) HR-well (n¼63) HR-MDD (n¼20) Statistics
Mean (SD) Mean (SD) Mean (SD) F/χ2 p Mean (SD) Mean (SD) Mean (SD) F/χ2 p
Age (years) 21.01 (2.45) 21.20 (2.88) 21.10 (2.82) 0.13 0.88 22.82 (2.73) 23.71 (2.84) 23.33 (2.98) 1.77 0.17
Gender (M:F) 40:53 44:48 9:10 0.46 0.80 21:41 29:34 7:13 2.12 0.35
Handedness (Right:other) 88:5 81:11 19:0 5.54 0.24 61:1 57:6 20:0 5.43 0.07
NART IQ 110.31 (8.00) 108.39 (9.37) 107.26 (6.80) 1.64 0.20 – – – – –
Time (years) 2.13 (0.22) 2.15 (0.22) 2.10 (0.13) 0.20 0.82 – – – – –
HAM-Db 0 (1) 0 (2) 1 (5) 9.79 0.01a 1 (3) 1 (2) 5 (12) 7.59 0.02a
YMRSb 0 (0) 0 (0) 0 (0) 3.48 0.18 0 (0) 0 (1) 0 (0) 0.79 0.68
Abbreviations: F, female; HAM-D, Hamilton Depression Rating Scale; HC, unaffected healthy control subjects; HR, high risk; HR-MDD, individuals at high risk for mood
disorders who were well at baseline but developed major depressive disorder during the follow-up period; HR-well, individuals at high risk of mood disorders who were
well at baseline and remained well during the follow-up period; M, male; NART, National Adult Reading Test; Time, Time between baseline and follow-up assessment; YMRS,
Young Mania Rating Scale.
a Signiﬁcant effect.
b Kruskal-Wallis test, median and interquartile presented for skewed variables.
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the right caudate (puncorrectedr0.024), with the HR-MDD group
having smaller volumes than the HC (pHSDr0.024) and the HR-well
(pHSDr0.016) group across time. Also, there was a nominally sig-
niﬁcant group-by-time interaction for the volume of the left amyg-
dala (puncorrectedr0.036). Post-hoc analyses revealed that the volume
of this structure decreased over time in the HR-well as compared to
the HC group that in turn displayed volumetric increases (pHSD
r0.024). No signiﬁcant interaction effects for the HR-MDD as
compared to the HC group (pHSDr0.504) and the HR-well as com-
pared to HR-MDD participants (pHSDr0.158) were found. These ef-
fects were only signiﬁcant at nominal level and did not survive FDR
correction.3.3. Correlation analysis
The correlation analysis yielded no signiﬁcant associations be-
tween any volume of the ROIs and depression severity as mea-
sured with the Hamilton Depression Rating Scale total score
(Table 3).Table 2
Longitudinal analysis of regional subcortical volumes.
HC HR-well H
Baseline
(n¼93)
Follow-up
(n¼62)
Baseline
(n¼92)
Follow-up
(n¼63)
B
(
Region Mean (SD) Mean (SD) Mean (SD) Mean (SD) M
L lat ventricle 6.69 (2.05) 6.98 (2.74) 7.17 (2.50) 7.28 (2.69) 5
R lat ventricle 6.04 (2.44) 6.27 (2.06) 6.48 (2.20) 6.56 (2.38) 5
L caudate 3.68 (0.43) 3.70 (0.53) 3.71 (0.44) 3.60 (0.45) 3
R caudate 3.83 (0.45) 3.89 (0.59) 3.88 (0.47) 3.83 (0.49) 3
L putamen 5.91 (0.78) 6.02 (0.83) 6.03 (0.72) 6.01 (0.82) 6
R putamen 5.71 (0.67) 5.81 (0.71) 5.72 (0.61) 5.69 (0.72) 5
L pallidum 1.94 (0.29) 1.93 (0.29) 1.87 (0.29) 1.88 (0.33) 1
R pallidum 1.86 (0.28) 1.85 (0.32) 1.83 (0.29) 1.79 (0.33) 1
L thalamus 6.58 (0.75) 6.60 (0.66) 6.56 (0.73) 6.38 (0.76) 6
R thalamus 6.62 (0.67) 6.68 (0.70) 6.56 (0.73) 6.48 (0.79) 6
L hippocampus 3.50 (0.45) 3.47 (0.49) 3.49 (0.46) 3.41 (0.40) 3
R hippocampus 3.58 (0.46) 3.65 (0.52) 3.56 (0.47) 3.47 (0.38) 3
L amygdala 1.77 (0.32) 1.83 (0.33) 1.79 (0.35) 1.67 (0.27) 1
R amygdala 1.96 (0.30) 1.97 (0.30) 1.92 (0.33) 1.92 (0.27) 2
Volumes are measured in cm3, p-values are presented uncorrected for multiple comparis
high risk for mood disorders who were well at baseline but developed major depressiv
disorders who were well at baseline and remained well during the follow-up period; L3.4. Analysis of potential confounders
To eliminate the potential confounding effects of familial re-
latedness of some subjects, the longitudinal analyses were re-
peated, excluding randomly individuals from the same family
(Supplemental Table S1). This analysis similarly yielded no sig-
niﬁcant effect of group, time or group-by-time interaction. Also,
when excluding medicated HR-MDD subjects from the analyses,
no signiﬁcant effects were observed (Supplemental Table S2).4. Discussion
To the best of our knowledge, this is one of the ﬁrst prospective
longitudinal studies investigating subcortical brain volumes in fa-
milial high-risk of mood disorders individuals who were un-
affected at study entry and either had an onset of MDD or re-
mained well during the two-year follow-up time interval. In con-
trast to our initial hypothesis, we observed no signiﬁcant volu-
metric differences between the groups for any ROI using the cur-
rent approach over a two-year time interval between baseline andR-MDD Statistics
aseline
n¼19)
Follow-up
(n¼20)
Group effect Time effect GroupXTime
ean (SD) Mean (SD) F p F p F p
.71 (2.45) 5.57 (2.65) 1.25 0.29 1.80 0.18 0.62 0.54
.40 (2.83) 5.46 (2.01) 0.79 0.46 0.88 0.35 0.13 0.88
.53 (0.46) 3.44 (0.51) 1.74 0.18 2.03 0.16 1.27 0.28
.62 (0.47) 3.51 (0.50) 3.81 0.02 0.48 0.49 0.92 0.40
.09 (0.77) 5.77 (0.83) 0.11 0.90 1.22 0.27 2.42 0.09
.82 (0.65) 5.40 (0.79) 0.45 0.64 2.34 0.13 2.52 0.08
.94 (0.29) 1.90 (0.27) 1.27 0.28 0.19 0.66 0.26 0.78
.94 (0.29) 1.83 (0.25) 1.04 0.36 2.93 0.09 0.58 0.56
.66 (0.75) 6.39 (0.74) 0.88 0.42 2.98 0.09 1.42 0.24
.75 (0.76) 6.55 (0.79) 1.10 0.33 0.85 0.36 1.04 0.36
.61 (0.54) 3.44 (0.53) 0.37 0.69 2.64 0.11 0.28 0.76
.65 (0.59) 3.38 (0.54) 1.58 0.21 3.33 0.07 2.54 0.08
.79 (0.34) 1.72 (0.23) 1.55 0.22 1.14 0.29 3.40 0.04
.06 (0.33) 1.91 (0.26) 1.31 0.27 1.20 0.28 1.12 0.33
on. Abbreviations: HC, unaffected healthy control subjects; HR-MDD, individuals at
e disorder during the follow-up period; HR-well, individuals at high risk of mood
, left; lat, ateral; R, right, SD, standard deviation.
Table 3
Correlation between regional subcortical volumes and severity of depressive
symptoms.
HC (n¼93) HR-well (n¼92) HR-MDD (n¼19)
Region R p R p R p
L lat ventricle 0.06 0.71 0.10 0.51 0.22 0.44
R lat ventricle 0.19 0.43 0.13 0.37 0.20 0.48
L caudate 0.11 0.47 0.27 0.06 0.04 0.88
R caudate 0.13 0.40 0.27 0.06 0.02 0.95
L putamen 0.16 0.29 0.05 0.74 0.02 0.94
R putamen 0.15 0.31 0.30 0.04 0.10 0.72
L pallidum 0.05 0.75 0.28 0.05 0.19 0.51
R pallidum 0.20 0.18 0.13 0.36 0.31 0.26
L thalamus 0.11 0.47 0.37 0.01 0.11 0.69
R thalamus 0.18 0.23 0.07 0.64 0.22 0.43
L hippocampus 0.06 0.71 0.19 0.19 0.15 0.59
R hippocampus 0.17 0.26 0.31 0.03 0.28 0.32
L amygdala 0.02 0.91 0.05 0.74 0.07 0.80
R amygdala 0.12 0.48 0.03 0.86 0.37 0.17
p-values are presented uncorrected for multiple comparison. Abbreviations: HC,
unaffected healthy control subjects; HR-MDD, individuals at high risk for mood
disorders who were well at baseline but developed major depressive disorder
during the follow-up period; HR-well, individuals at high risk of mood disorders
who were well at baseline and remained well during the follow-up period; L, left;
lat, lateral; R, right.
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by-time interactions were found. Similarly, the correlation analyses
yielded no signiﬁcant association between any subcortical brain
volume and depressive symptom severity. Excluding participants
of the same pedigree or medicated individuals did not alter these
results.
Of note, a nominal signiﬁcant group effect for the volume of the
right caudate was found, indicating smaller volumes in the HR-
MDD as compared to the other two study groups across both time
points. Furthermore, a nominal signiﬁcant group-by-time inter-
action was observed for the volume of the left amygdala. The in-
teraction was driven by the HR-well group displaying decreasing
left amygdala volume over time as compared to the HC group
which in turn showed a volumetric increase. Since both ﬁndings
did not survive correction for multiple testing however, these re-
sults should be interpreted with caution and we suggest to study
the volumes of the right caudate and left amygdala prospectively
in individuals at high familial risk using larger sample sizes to be
able to detect even slightest volume abnormalities.
Our ﬁnding of unaltered subcortical brain volumes in HR-well
subjects as compared to the HC group is in line with a recent
meta-analysis that found no evidence towards subcortical brain
volume abnormalities in unaffected close relatives of BD patients
(of n¼122–485 HC and n¼65–246 HR individuals, depending on
the brain structure analysed) (Fusar-Poli et al., 2012). Interestingly,
the few studies employing structural brain imaging techniques in
unaffected individuals with a close family history of MDD have
repeatedly detected abnormal hippocampus (Amico et al., 2011;
Baare et al., 2010; Rao et al., 2010; Romanczuk-Seiferth et al., 2014)
and amygdala (Lupien et al., 2011; Romanczuk-Seiferth et al., 2014)
volumes as compared to individuals with no family history of
MDD. Accordingly, this may suggest that speciﬁc subcortical brain
regions are differentially inﬂuenced by genetic and environmental
risk factors speciﬁc to MDD and BD, respectively. This hypothesis
would also be in line with a study by Saleh et al. (2012) who ob-
served opposing effects of a positive or negative family history of
MDD on the volume of the amygdala in depressed individuals.
Taken together, our ﬁndings imply that volumetric subcortical
brain abnormalities do not constitute a familial trait marker for
vulnerability to mood disorders in close BD relatives. However, it
may well be the case that subcortical brain abnormalities do serveas a vulnerability marker for mood disorders in individuals ex-
posed to distinct genetic and environmental risk factors. In line
with this hypothesis, Opel et al. (2015) detected gray matter re-
ductions in the hippocampus of individuals at high risk of MDD
because of the environmental risk factor of childhood maltreat-
ment but not in individuals at high risk of MDD because of a close
family history of the disease. By contrast, the familial risk in-
dividuals of their study showed gray matter reductions in cortical
brain regions, including the insula and orbitofrontal cortex.
The absence of volumetric subcortical brain abnormalities
across time in the HR-MDD group and the absence of group-by-
time interactions is opposed to cross-sectional meta-analytic and
mega-analytic ﬁndings that repeatedly detected volumetric ab-
normalities of the lateral ventricles, basal ganglia, hippocampus
and thalamus in patients with mood disorders (Arnone et al.,
2009, 2012; Bora et al., 2012; Hallahan et al., 2011; Kempton et al.,
2008, 2011; Koolschijn et al., 2009; McDonald et al., 2004).
Moreover, these ﬁndings are partly in contrast to a recent pro-
spective longitudinal study by Whittle et al. (2014) who found
volumetric changes in the hippocampus, amygdala and putamen
to be associated with an onset of depression in individuals initially
presenting with prodromal depressive symptoms. However, it
appears likely that this discrepancy in ﬁndings is due to systematic
differences in the study design. In particular, Whittle et al. (2014)
studied young adolescents who were on average only 12 years of
age at study entrance and used a longer inter-scan interval of four
years. Moreover, individuals were initially presenting with puta-
tive prodromal symptoms while our high-risk participants were
selected based on a positive family history of BD, with research on
other psychiatric conditions like psychosis indicating that struc-
tural brain abnormalities are more pronounced in clinical high risk
versus familial high risk individuals (Smieskova et al., 2013). Most
of all, it appears likely that our high-risk study participants who
developed MDD were exposed to distinct genetic and environ-
mental risk factors associated with a family history of BD as
compared to individuals with no family history of BD. All in all, our
results provide a ﬁrst hint to suggest that volumetric subcortical
brain abnormalities may not predate an onset of MDD or emerge
as a consequence of illness-speciﬁc mechanisms linked to the
onset of the disorder in close relatives of BD patients. Rather, we
hypothesize that volumetric abnormalities may only emerge dur-
ing the course of the disorder. Subcortical brain volumes may also
be inﬂuenced by the severity or length of illness, the age at illness
onset or the length and type of psychopharmacological treatment.
Using functional MRI approaches, our research group has pre-
viously shown that the high-risk group at baseline, when all in-
dividuals were still unaffected by disease, show abnormal amyg-
dala activation during an executive processing task (Whalley et al.,
2011) and that amygdala activation is related to cumulative genetic
risk for BD using polygenic risk proﬁling (Whalley et al., 2012).
Moreover, we have shown that HR-MDD as compared to HR-well
subjects exhibit increased brain activation in cortico-thalamic-
limbic regions encompassing the thalamus prior to illness onset
(Whalley et al., 2015, 2013). The ﬁndings of the present study
suggest that the observed aberrant brain activity in the high-risk
group as whole or the HR-MDD group appears to be unrelated to
volumetric structural brain abnormalities in the same brain region.
The strengths of this study are its longitudinal study design, the
assessment of brain morphology prior to illness onset and the
relatively large sample size of high-risk and control individuals.
Another advantage relates to the relatively young age of the par-
ticipants at study entrance since early adulthood is considered a
critical phase for both illness onset as well as neurodevelopmental
processes (Giedd, 2004; Kessler et al., 2005). Furthermore, all
participants underwent careful clinical assessment at both ap-
pointments and medication effects as well as effects of familial
M. Papmeyer et al. / Psychiatry Research: Neuroimaging 248 (2016) 119–125124relatedness were ruled out. All brain scans were acquired at the
same MRI scanner using an identical imaging protocol at both
visits and the MRI data processing was conducted in an identical
way with thoroughly validated methods.
Nevertheless, some limitations need to be addressed. First, it
cannot be ruled out that currently unaffected HR-well subjects
may have an onset of MDD in the future. Second, it appears likely
that some of the HR-MDD participants may develop BD in the
future since longitudinal studies have documented that the ma-
jority of high-risk individuals who went on to develop BD them-
selves had depressive episodes years before conversion (Duffy,
2010; Hillegers et al., 2005). Future follow-up examinations of our
study cohort will clarify these aspects. Third, our sample size of 20
HR-MDD subjects is relatively small which diminishes statistical
power to detect small-sized volumetric differences between the
groups or over time. Fourth, our study groups differed with regard
to their depression symptom severity at baseline. However, the
median of the Hamilton Depression Rating Scale total score was
only 1 in the HR-MDD group, corresponding to only sub-syn-
dromal depression symptoms. Furthermore, no relationship be-
tween depression symptom severity and the subcortical brain
volumes was observed. Accordingly, it appears unlikely that
group-differences in mood at baseline have inﬂuenced our results.
Fifth, the precise onset of MDD could not be determined so that it
remains unknown whether the duration of the depressive episode
until the second MRI scan was obtained might have inﬂuenced the
results. Sixth, the two-year follow-up period may have been re-
latively short for brain changes to occur at such a magnitude that
they are detectable with our sample size. Future follow-up ex-
aminations of our study cohort will further explore this aspect.
Finally, it has been shown that the reliability of subcortical brain
structure segmentations using FreeSurfer is reduced in brain re-
gions that are small in volume such as the amygdala as compared
to larger brain structures (Morey et al., 2010).
In summary, no signiﬁcant volumetric abnormalities of the
lateral ventricles, basal ganglia, thalamus, hippocampus and
amygdala were detected in individuals at high familial risk of
mood disorders, regardless of an onset of MDD or not. Accordingly,
it can be concluded that subcortical volumetric brain abnormal-
ities that are often observed in mood disorders only emerge dur-
ing the course of illness and are not related to the illness onset or
enhanced familial risk for the disorder, at least in close BD re-
latives. These ﬁndings advance our understanding of the neuro-
pathological processes underlying mood disorders. Future pro-
spective longitudinal studies are required that particularly in-
vestigate the course of subcortical brain volume development
before and after the onset of depression using longer time
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